Latest Manufacturing Capacity News

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

EVZ Limited reported a 14% revenue increase to $123.1 million and a 213% jump in net profit after tax to $3.87 million for FY2026, resuming dividends for the first time since 2010.

DXN Limited has landed a A$12.2 million contract to deliver a 2MW AI High-Performance Computing modular data centre, expanding its AI HPC order book to about A$21 million and positioning the company for further growth in a booming market.

IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.

AnteoTech has formalised a strategic alliance with South Korea’s Xerabrid to co-develop and commercialise a breakthrough battery separator combining their proprietary technologies, targeting high-performance applications in eVTOL, EVs, and consumer electronics.

Telix Pharmaceuticals returned to profit in H1 2026, driven by strong U.S. sales of Illuccix and Gozellix, a $40 million upfront from Regeneron collaboration, and expanded R&D investment.

Wagners Holding Company Limited (ASX:WGN) reported a 17% revenue increase to $504 million and a 78.5% surge in net profit after tax to $40.6 million for FY26, driven by strong growth in Construction Materials and Composite Fibre Technologies.

Adrad Holdings delivered a 15% rise in net profit after tax for FY26, driven by operational efficiency and growth in engineered heat transfer solutions, alongside a 15% dividend increase.